CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.

@article{Hidestrand2001CYP2B6AC,
  title={CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.},
  author={Mats Hidestrand and Mikael Oscarson and Jarmo S. Salonen and Leena Nyman and Outi Pelkonen and Miia Turpeinen and Magnus Ingelman-Sundberg},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2001},
  volume={29 11},
  pages={1480-4}
}
In view of conflicting data in the literature regarding the enzyme(s) responsible for metabolism of selegiline, a drug used in the treatment of Parkinson's disease, investigations were carried out in vitro using the human cytochrome P450 enzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 recombinantly expressed in yeast to elucidate the enzyme specificity in selegiline metabolism. In the yeast microsomes used, desmethylselegiline and levomethamphetamine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant

  • TB Andersson, H Sjöberg, +7 authors MJ Gómez-Lechón
  • Drug Metab Disp 29:712–720
  • 2001
2 Excerpts

Similar Papers

Loading similar papers…